Sort   by:  
 Page size 
MetabolomicsSoftware tool for internal standard based normalization of lipids, and effect of data-processing strategies on resulting values

BACKGROUND: Lipidomics, the comprehensive measurement of lipids within a biological system or substrate, is an emerging field with significant potential for improving clinical diagnosis and our understanding of health and disease. While lipids diverse biological roles contribute ...

2022-05-17 | MTBLS710 | MetaboLights
UnknownLisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Not available
S-EPMC11753452 | biostudies-literature
UnknownStudy protocol for the safety and efficacy of probiotic therapy on days alive and out of hospital in adult ICU patients: the multicentre, randomised, placebo-controlled Restoration Of gut microflora in Critical Illness Trial (ROCIT).
Not available
S-EPMC7311035 | biostudies-literature
UnknownSafety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
Not available
S-EPMC8883262 | biostudies-literature
UnknownNodavirus RNA replication crown architecture reveals proto-crown precursor and viral protein A conformational switching.
Not available
S-EPMC9945985 | biostudies-literature
UnknownStepwise evaluation for the risk of metabolic unhealthiness and significant non-alcoholic fatty liver disease in India.
Not available
S-EPMC10306046 | biostudies-literature
UnknownFour-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Not available
S-EPMC10862253 | biostudies-literature
TranscriptomicsBlood RNA from metastatic Clear Cell Renal Carcinoma patients before or after treatment with nivolumab
Blood samples obtained at Cycle 1 Day 1, Cycle 1 Day 2 or at Cycle 2 Day 8 (i.e. before treatment, 24 hours after treatment or Week 4) from metastatic clear cell RCC patients treated with 0.2mpk, 3mpk or 10mpk (as 2nd or further line of therapy; Arms A,B,C) or 10mpk (as first line therapy; Arm D) of...
ORGANISM(S): Homo sapiens 
2016-05-15 | E-MTAB-3219 | biostudies-arrayexpress
TranscriptomicsBiopsies from metastatic Clear Cell Renal Carcinoma before or after treatment with nivolumab
Tumor core needle biopsies from kidney or metastatic sites obtained at trial enrollment i.e. Screen and/or at Cycle 2 Day 8 (i.e.Week 4) from metastatic clear cell RCC patients treated with 0.2mpk, 3mpk or 10mpk (as 2nd or further line of therapy; Arms A,B,C) or 10mpk (as first line therapy; Arm D) ...
ORGANISM(S): Homo sapiens 
2016-05-15 | E-MTAB-3218 | biostudies-arrayexpress
UnknownVirologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.
Not available
S-EPMC3280244 | biostudies-literature
Sort   by:  
 Page size